
ABSTRACT

A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR^3; R^1 is a hydrogen atom or a halogen atom; R^2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R^3 is a halogen atom. However, R^1 is a halogen atom when X is CR^3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.



[1]